Jump to navigation Sign in to your account Language Flag Enter your keywords <non> Company About Fujirebio Company presentation Environmental engagement Partnerships & Alliances Purchasing Quality ISO and GMP Certificates Contact Find your local contact Fujirebio Europe (Belgium) Fujirebio Diagnostics (Sweden) Let's stay in touch Follow us on LinkedIn Sign up for our newsletter Products & services Product browser About our products EIA SERODIA® Quality Regulatory product documents Resource Center Background articles Biomarkers: β-amyloid and tau Biomarker: HBcrAg Biomarker: HE4 Biomarker: KL-6 Biomarker: Mesothelioma Biomarker: Pepsinogen Biomarker: PIVKA-II Support Frequently Asked Questions Regulatory / Quality documents Safety Data Sheets Certificates of Analysis CE Declarations of Conformity Assigned Value Sheets IFUs / Package Inserts Automated Test Procedures ISO and GMP Certificates Order Handling Conditions of sale Fujirebio Europe distributor extranet Careers Why work at Fujirebio? Job offers Spontaneous application Media & Events News Events Sign up for our newsletter Contact Let's stay in touch Follow us on LinkedIn Sign up for our newsletter Customer satisfaction survey How to contact us Find your local contact Fujirebio Europe (Belgium) Fujirebio Diagnostics (Sweden) You are here Home › Biomarker: PIVKA-II (Protein Induced Vitamin K Absence or Antagonist-II) Biomarker: PIVKA-II (Protein Induced Vitamin K Absence or Antagonist-II) A biomarker of liver cells for the management of hepatocellular carcinoma (HCC) PIKVA-II is an immature form of prothrombin also known as DCP (Des-gamma-Carboxy Prothrombin), vitamin Kcoagulation factor, synthesized in the liver. In absence of vitamin K or when its action is antagonized (warfarin), PIVKA-II is released into the blood. Phenotypic changes of liver cells enhance the production of PIVKA-II via impairments of vitamin K uptake1. PIVKA-II is an established HCC marker. PIVKA-II serum and tissue overexpression are related to worse tumor behavior2-3, such as the presence of (micro) vascular invasion and intrahepatic metastasis of HCC cells and may indicate a poor prognostic outcome. Lumipulse® G PIVKA-II PIVKA-II is a biomarker of liver cells for the management of hepatocellular carcinoma (HCC). Our Lumipulse G immunoreaction cartridges are for in vitro diagnostic (IVD) use with the LUMIPULSE G system for the quantitative measurement of protein induced vitamin K absence or antagonist-II (PIVKA-II) in serum. Read more here CLOSE You can change the country filter for contents in our website. You will then see local contact information and other information available for that country. Please choose your country in the list below: Select * Afghanistan Aland Islands Albania Algeria Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Cote d’Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, the former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Martinique Mauritania Mauritius Mayotte Mexico Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Norway Oman Pakistan Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Reunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunesia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Viet Nam Virgin Islands, British Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Check this box if you want our website to remember your choice every time you come back. ICON Close Sign up for our newsletters Get monthly updates about product and company news and resources directly in your inbox. Read more or sign up below: First name * Name * E-mail address * We do NOT share emails with third parties and you can unsubscribe at any time. Leave this field blank Articles related to biomarker: pivka-ii (protein induced vitamin k absence or antagonist-ii) PIVKA-II, a biomarker for early diagnosis of hepatocellular carcinoma (HCC) 18/05/2016 Author: Dr Phuong-Nhi BORIES - Praticien Hospitalier - Service de Biochimie - Pr Luc CYNOBER - HUPC - Hôpital Cochin - France The Clinical Chemistry Department of the Hôpital Cochin, part of «Hôpitaux Universitaires Paris Centre» (HUPC) is equipped with an automated platform for routine assays including general biochemistry parameters and common tumor markers as well as dedicated analyzers f Read this article » Clinical background of Hepatocellular carcinoma (HCC) 25/09/2015 Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide with a high rate of mortality and an increasing incidence. Read this article » PIVKA-II References 25/09/2015 Murata et al. Int J Oncol 2010; 36:161-170 Inagaki et al. BioScience Trends 2008; 2(2):53-60 Shirabe et al. J Surg Oncol 2007; 95:235-240 Tateishi et al. Hepatol Int 2008; 2:17-30 Hu et al. Int J Mol Sci 2013; 14:23559-580 Read this article » Products related to biomarker: pivka-ii (protein induced vitamin k absence or antagonist-ii) Lumipulse® G PIVKA-II Show all products Company About Fujirebio Company presentation Environmental engagement Partnerships & Alliances Purchasing Quality ISO and GMP Certificates Contact Find your local contact Fujirebio Europe (Belgium) Fujirebio Diagnostics (Sweden) Let's stay in touch Follow us on LinkedIn Sign up for our newsletter Products & services Product browser About our products EIA SERODIA® Quality Regulatory product documents Resource Center Background articles Biomarkers: β-amyloid and tau Biomarker: HBcrAg Biomarker: HE4 Biomarker: KL-6 Biomarker: Mesothelioma Biomarker: Pepsinogen Biomarker: PIVKA-II Support Frequently Asked Questions Regulatory / Quality documents Safety Data Sheets Certificates of Analysis CE Declarations of Conformity Assigned Value Sheets IFUs / Package Inserts Automated Test Procedures ISO and GMP Certificates Order Handling Conditions of sale Fujirebio Europe distributor extranet Careers Why work at Fujirebio? Job offers Spontaneous application Media & Events News Events Sign up for our newsletter Contact Let's stay in touch Follow us on LinkedIn Sign up for our newsletter Customer satisfaction survey How to contact us Find your local contact Fujirebio Europe (Belgium) Fujirebio Diagnostics (Sweden) Contact Terms & Conditions Privacy Policy Cookie Policy © Fujirebio